RAB42: A Prognostic Marker Associated with Tumor Immune Microenvironment in Bladder Cancer

RAB42, member rat sarcoma oncogene family was proved to play a key role in cancer-promoting progression. However, its function in the progression of bladder cancer was still uncertain. We explored the role of RAB42, member rat sarcoma oncogene family in bladder cancer and pan-cancer using bioinformatics analysis, including expression, prognostic, genetic alteration, functional pathways, tumor microenvironment and drug resistance. Our results indicated that RAB42, member rat sarcoma oncogene family expression was increased in most cancers, including bladder cancer and that its expression generally indicated poorer patient prognosis. In addition, RAB42, member rat sarcoma oncogene family expression was positively associated with most immune cells, such as tumor-associated macrophages and Tregs. Elevated expression of RAB42, member rat sarcoma oncogene family predicted resistance to several anti-tumor drugs. In summary, our study showed that RAB42, member rat sarcoma oncogene family is a potential oncogene and prognostic marker in bladder cancer and pan-cancer. Elevated RAB42, member rat sarcoma oncogene family expression indicated tumor immunosuppressive microenvironment.